Ranjeet Singh is the Lead – Public and Government Affairs at Boehringer Ingelheim, based in New Delhi. In this role, he spearheads the company’s strategic engagement with government institutions, regulatory authorities, non-profit organizations, and industry associations, shaping policy dialogue and advancing collaboration across India’s healthcare landscape.

With deep expertise spanning corporate affairs, market access, patient advocacy, and public policy, Ranjeet is known for building trusted, multi-stakeholder partnerships that drive sustainable health system outcomes. His work is anchored in aligning policy priorities with patient needs, enabling access to innovative therapies, and strengthening the broader healthcare ecosystem.

Prior to joining Boehringer Ingelheim, Ranjeet held impactful roles at prominent pharmaceutical organizations, including Takeda, Baxter, Pfizer, and MSD. Over a 19+ year career, he has led strategic policy advocacy, high-level stakeholder engagement, and access initiatives across a range of therapeutic areas.
Ranjeet is a strong proponent of collaborative, cross-sector approaches to addressing India’s most pressing healthcare challenges, with particular focus on hemoglobinopathies, oncology, non-communicable diseases, and rare diseases. His nuanced understanding of India’s policy environment, combined with a commitment to long-term, patient-centric impact, positions him as a key contributor to Boehringer Ingelheim’s mission of advancing health outcomes and innovation in India.